stockportfolio.pro logostockportfolio.pro
Stocks Screener Start 7-day free trial
Stocks / NBIX / Revenue

Neurocrine Biosciences, Inc. Revenue 2009–2025

Neurocrine Biosciences, Inc. (NBIX) annual revenue by fiscal year, computed from SEC filings. Compound growth +53.7%/yr over 16 years.

Fiscal yearRevenueChange (YoY)
FY 2025$2.86B+21.4%
FY 2024$2.36B+24.8%
FY 2023$1.89B+26.8%
FY 2022$1.49B+31.3%
FY 2021$1.13B+8.4%
FY 2020$1.05B+32.7%
FY 2019$788.10M+74.7%
FY 2018$451.20M+179.2%
FY 2017$161.63M+977.5%
FY 2016$15.00M-24.1%
FY 2015$19.77M
FY 2014$0-100.0%
FY 2013$2.92M-94.5%
FY 2012$53.14M-31.4%
FY 2011$77.41M+131.1%
FY 2010$33.50M+1034.5%
FY 2009$2.95M

Source: Neurocrine Biosciences, Inc. SEC filings — income statement (10-K). Refreshed nightly.

See the full picture for Neurocrine Biosciences, Inc.

Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.

Open the interactive view — free

Neurocrine Biosciences, Inc. — frequently asked questions

What is Neurocrine Biosciences, Inc.'s revenue?

Neurocrine Biosciences, Inc. (NBIX) reported revenue of $2.86B for fiscal year 2025, per its SEC filings.

How has Neurocrine Biosciences, Inc.'s revenue changed over time?

Between fiscal 2009 and 2025, NBIX's revenue grew at roughly 53.7% per year (compound annual rate), from $2.95M to $2.86B.

Where does this data come from?

Figures are computed from Neurocrine Biosciences, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.

More NBIX financial history

Full NBIX fundamentals page → · All 1,500+ companies →